OSE Immunotherapeutics’ immuno-oncology pipeline is comprised of four programs, three of which are currently in clinical status.
The most advanced program is its Phase 3 trial with TEDOPI®, a patented combination of 10 neo-epitopes. Tedopi® is being evaluated in non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure.
A Phase 2 is also planned (early 2019) in pancreatic cancer in collaboration with the GERCOR, a leading clinical research association that includes 300 cancer centers in France.
OSE Immunotherapeutics is also investigating OSE-172, a first-in-class myeloid checkpoint inhibitor targeting the SIRPα / CD47 receptor pathway. In 2018, OSE Immunotherapeutics and Boehringer Ingelheim initiated a partnership covering the product’s development and commercialization in this promising new area of immuno-oncology.
Additionally, OSE Immunotherapeutics, in collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, is investigating the potential for OSE- 703, a cytotoxic monoclonal antibody against the alpha chain of Interleukin-7 Receptor (IL7R), in a number of solid tumor types with non-small cell lung cancer (NSCLC) as the primary cancer model.
Several new pipeline candidates should emerge in the near future in the immuno-oncology area.
- Indication NSCLC
- Pre-Clinical POC
- Phase 1
- Phase 2
- Phase 3 EU-US-lsr